Health
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
BERLIN, February 27, 2026--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The dose for expansion was successfully identified, with ≥80% of patients achieving a PSA50 response at the expansion dose.
About this update from Bayer Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/922307591ce7e33d1c4af5a8b78c21d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HQMFyANFCCk.QOvZV51Jbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/922307591ce7e33d1c4af5a8b78c21d6","width":400,"height":400}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"225Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC)","length":183,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Data from PAnTHa, the global Phase I first-in-human, dose-escalation study were presented during the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA","length":196,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Data support advancing 225Ac-PSMA-Trillium to the next phase of development","length":75,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Prostate cancer is the second most common diagnosed cancer in men1, with less than three years median survival among metastatic patients, who have developed castration-resistance2","length":179,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"TAT is a strategic pillar of precision oncology at Bayer, with the potential to shift the treatment paradigm for patients","length":121,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":754,"olType":false},{"type":"text","content":"Not intended for UK Media","length":25,"tagName":"p"},{"type":"text","content":"BERLIN, February 27, 2026--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The dose for expansion was successfully identified, with ≥80% of patients achieving a PSA50 response at the expansion dose.","length":517,"tagName":"p"},...